1
|
Lu J, Song J, Zhang P, Huang Y, Lu X, Dai H, Xi J. Biomineralized Polydopamine Nanoparticle-Based Sodium Alginate Hydrogels for Delivery of Anti-serine/Threonine Protein Kinase B-Rapidly Accelerated Fibrosarcoma siRNA for Metastatic Melanoma Therapy. ACS NANO 2023; 17:18318-18331. [PMID: 37690074 DOI: 10.1021/acsnano.3c05563] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/12/2023]
Abstract
Malignant melanoma, as a highly aggressive skin cancer, is strongly associated with mutations in serine/threonine protein kinase B-RAF (BRAF, where RAF stands for rapidly accelerated fibrosarcoma). Targeted therapy with anti-BRAF small interfering RNA (siBRAF) represents a crucial aspect of metastatic melanoma treatment. In this study, an injectable hydrogel platform based on sodium alginate (SA), with multifunctions of photothermal and Ca2+-overload cell apoptosis, was explored as a siBRAF carrier for metastatic melanoma therapy. We employed polydopamine nanoparticles (PDAs) as a photothermal core and constructed a calcium phosphate (CaP) shell via biomineralization (PDA@CaP) to load siBRAF (PDA@siBRAF/CaP). The pH-sensitive CaP shell facilitated the release of Ca2+ under the weakly acidic tumor microenvironment, triggering the gelation of PDA@siBRAF/CaP-SA to localized release siBRAF at tumor sites with the interruption of the RAS-RAF-MEK-ERK (MAPK) pathway. Besides, the continuous release of Ca2+ could also lead to Ca2+-overload cell apoptosis. Moreover, the photothermal effect of PDA regulated the release kinetics, resulting in coordinated therapeutic abilities of individual components in the PDA@siBRAF/CaP-SA hydrogels. Consequently, the effective inhibition of tumor growth and metastasis was achieved in vitro and in vivo using a highly metastatic melanoma cell line B16F10 as the model, by combining photothermal ablation, Ca2+ overload, and BRAF silencing. Our work provides a proof-of-concept for an injectable hydrogel system that simultaneously targets multiple mechanisms involved in melanoma progression and has the potential to be translated into clinical use for the metastatic melanoma therapy.
Collapse
Affiliation(s)
- Jianxiu Lu
- School of Medicine, Institute of Translational Medicine, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, China
- Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou, Jiangsu 225009, China
| | - Jixin Song
- School of Medicine, Institute of Translational Medicine, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, China
- Jiangsu Key Laboratory of Experimental & Translational Non-coding RNA Research, Yangzhou, Jiangsu 225009, China
| | - Peiying Zhang
- School of Medicine, Institute of Translational Medicine, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, China
| | - Ying Huang
- School of Medicine, Institute of Translational Medicine, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, China
| | - Xiaomin Lu
- Department of Oncology, Affiliated Haian Hospital of Nantong University, Nantong, Jiangsu 226600, China
| | - Hua Dai
- School of Medicine, Institute of Translational Medicine, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, China
- Jiangsu Key Laboratory of Experimental & Translational Non-coding RNA Research, Yangzhou, Jiangsu 225009, China
| | - Juqun Xi
- School of Medicine, Institute of Translational Medicine, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, China
- Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou, Jiangsu 225009, China
| |
Collapse
|
2
|
Schafer C, Young D, Singh H, Jayakrishnan R, Banerjee S, Song Y, Dobi A, Petrovics G, Srivastava S, Srivastava S, Sesterhenn IA, Chesnut GT, Tan SH. Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens. J Immunol Methods 2023; 518:113493. [PMID: 37196930 PMCID: PMC10802095 DOI: 10.1016/j.jim.2023.113493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Revised: 05/10/2023] [Accepted: 05/13/2023] [Indexed: 05/19/2023]
Abstract
BACKGROUND Aberrant ETV1 overexpression arising from gene rearrangements or mutations occur frequently in prostate cancer, round cell sarcomas, gastrointestinal stromal tumors, gliomas, and other malignancies. The absence of specific monoclonal antibodies (mAb) has limited its detection and our understanding of its oncogenic function. METHODS An ETV1 specific rabbit mAb (29E4) was raised using an immunogenic peptide. Key residues essential for its binding were probed by ELISA and its binding kinetics were measured by surface plasmon resonance imaging (SPRi). Its selective binding to ETV1 was assessed by immunoblots and immunofluorescence assays (IFA), and by both single and double-immuno-histochemistry (IHC) assays on prostate cancer tissue specimens. RESULTS Immunoblot results showed that the mAb is highly specific and lacked cross-reactivity with other ETS factors. A minimal epitope with two phenylalanine residues at its core was found to be required for effective mAb binding. SPRi measurements revealed an equilibrium dissociation constant in the picomolar range, confirming its high affinity. ETV1 (+) tumors were detected in prostate cancer tissue microarray cases evaluated. IHC staining of whole-mounted sections revealed glands with a mosaic staining pattern of cells that are partly ETV1 (+) and interspersed with ETV1 (-) cells. Duplex IHC, using ETV1 and ERG mAbs, detected collision tumors containing glands with distinct ETV1 (+) and ERG (+) cells. CONCLUSIONS The selective detection of ETV1 by the 29E4 mAb in immunoblots, IFA, and IHC assays using human prostate tissue specimens reveals a potential utility for the diagnosis, the prognosis of prostate adenocarcinoma and other cancers, and the stratification of patients for treatment by ETV1 inhibitors.
Collapse
Affiliation(s)
- Cara Schafer
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Denise Young
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Harpreet Singh
- Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA
| | - Rahul Jayakrishnan
- Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA
| | - Sreedatta Banerjee
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Yingjie Song
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Albert Dobi
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Gyorgy Petrovics
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA
| | - Sudhir Srivastava
- Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
| | - Shiv Srivastava
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA
| | | | - Gregory T Chesnut
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA; Urology Service, Walter Reed National Military Medical Center, Bethesda, MD, 20852, USA
| | - Shyh-Han Tan
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA.
| |
Collapse
|
3
|
Ferreira WAS, Amorim CKN, Burbano RR, Villacis RAR, Marchi FA, Medina TS, Lima MMCD, Oliveira EHCD. Genomic and transcriptomic characterization of the human glioblastoma cell line AHOL1. ACTA ACUST UNITED AC 2021; 54:e9571. [PMID: 33470396 PMCID: PMC7812907 DOI: 10.1590/1414-431x20209571] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Accepted: 10/26/2020] [Indexed: 01/08/2023]
Abstract
Cancer cell lines are widely used as in vitro models of tumorigenesis, facilitating fundamental discoveries in cancer biology and translational medicine. Currently, there are few options for glioblastoma (GBM) treatment and limited in vitro models with accurate genomic and transcriptomic characterization. Here, a detailed characterization of a new GBM cell line, namely AHOL1, was conducted in order to fully characterize its molecular composition based on its karyotype, copy number alteration (CNA), and transcriptome profiling, followed by the validation of key elements associated with GBM tumorigenesis. Large numbers of CNAs and differentially expressed genes (DEGs) were identified. CNAs were distributed throughout the genome, including gains at Xq11.1-q28, Xp22.33-p11.1, Xq21.1-q21.33, 4p15.1-p14, 8q23.2-q23.3 and losses at Yq11.21-q12, Yp11.31-p11.2, and 15q11.1-q11.2 positions. Nine druggable genes were identified, including HCRTR2, ETV1, PTPRD, PRKX, STS, RPS6KA6, ZFY, USP9Y, and KDM5D. By integrating DEGs and CNAs, we identified 57 overlapping genes enriched in fourteen pathways. Altered expression of several cancer-related candidates found in the DEGs-CNA dataset was confirmed by RT-qPCR. Taken together, this first comprehensive genomic and transcriptomic landscape of AHOL1 provides unique resources for further studies and identifies several druggable targets that may be useful for therapeutics and biologic and molecular investigation of GBM.
Collapse
Affiliation(s)
- W A S Ferreira
- Laboratório de Cultura de Tecidos e Citogenética, SAMAM, Instituto Evandro Chagas, Ananindeua, PA, Brasil
| | - C K N Amorim
- Laboratório de Cultura de Tecidos e Citogenética, SAMAM, Instituto Evandro Chagas, Ananindeua, PA, Brasil
| | - R R Burbano
- Laboratório de Citogenética Humana, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil.,Núcleo de Pesquisas em Oncologia, Hospital Universitário João de Barros Barreto, Belém, PA, Brasil.,Laboratório de Biologia Molecular, Hospital Ophir Loyola, Belém, PA, Brasil
| | - R A R Villacis
- Departamento de Genética e Morfologia, Instituto de Ciências Biológicas, Universidade de Brasília, Brasília, DF, Brasil
| | - F A Marchi
- Centro Internacional de Pesquisa, A.C. Camargo Cancer Center, São Paulo, SP, Brasil
| | - T S Medina
- Centro Internacional de Pesquisa, A.C. Camargo Cancer Center, São Paulo, SP, Brasil
| | - M M C de Lima
- Instituto de Ciências Biológicas, Faculdade de Biomedicina, Universidade Federal do Pará, Belém, PA, Brasil
| | - E H C de Oliveira
- Laboratório de Cultura de Tecidos e Citogenética, SAMAM, Instituto Evandro Chagas, Ananindeua, PA, Brasil.,Instituto de Ciências Exatas e Naturais, Faculdade de Ciências Naturais, Universidade Federal do Pará, Belém, PA, Brasil
| |
Collapse
|
4
|
Dinhof C, Pirker C, Kroiss P, Kirchhofer D, Gabler L, Gojo J, Lötsch-Gojo D, Stojanovic M, Timelthaler G, Ferk F, Knasmüller S, Reisecker J, Spiegl-Kreinecker S, Birner P, Preusser M, Berger W. p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction. Cancers (Basel) 2020; 12:cancers12113205. [PMID: 33143299 PMCID: PMC7693367 DOI: 10.3390/cancers12113205] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 10/13/2020] [Accepted: 10/26/2020] [Indexed: 01/31/2023] Open
Abstract
Simple Summary ETS transcription factors are potent oncogenic drivers in several cancer types and represent promising therapeutic targets. However, molecular factors influencing response to ETS factor inhibition are widely unknown so far. Here, we uncover that sensitivity of cancer cells against ETS factor blockade by the small molecule inhibitor YK-4-279 is strongly promoted by p53 loss in a MAPK-driven background. Induction of a parthanatos-like cell death based on a deregulated MAPK/ETS1/p53/PARP1 signal axis is identified as underlying molecular mechanism. Hence, this study suggests a novel and biomarker-driven therapeutic strategy for p53-deleted tumours, generally known for their profound therapy resistance. Abstract The small-molecule E26 transformation-specific (ETS) factor inhibitor YK-4-279 was developed for therapy of ETS/EWS fusion-driven Ewing’s sarcoma. Here we aimed to identify molecular factors underlying YK-4-279 responsiveness in ETS fusion-negative cancers. Cell viability screenings that deletion of P53 induced hypersensitization against YK-4-279 especially in the BRAFV600E-mutated colon cancer model RKO. This effect was comparably minor in the BRAF wild-type HCT116 colon cancer model. Out of all ETS transcription factor family members, especially ETS1 overexpression at mRNA and protein level was induced by deletion of P53 specifically under BRAF-mutated conditions. Exposure to YK-4-279 reverted ETS1 upregulation induced by P53 knock-out in RKO cells. Despite upregulation of p53 by YK-4-279 itself in RKOp53 wild-type cells, YK-4-279-mediated hyperphosphorylation of histone histone H2A.x was distinctly more pronounced in the P53 knock-out background. YK-4-279-induced cell death in RKOp53-knock-out cells involved hyperPARylation of PARP1, translocation of the apoptosis-inducible factor AIF into nuclei, and induction of mitochondrial membrane depolarization, all hallmarks of parthanatos. Accordingly, pharmacological PARP as well as BRAFV600E inhibition showed antagonistic activity with YK-4-279 especially in the P53 knock-out background. Taken together, we identified ETS factor inhibition as a promising strategy for the treatment of notoriously therapy-resistant p53-null solid tumours with activating MAPK mutations.
Collapse
Affiliation(s)
- Carina Dinhof
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
- Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria;
| | - Christine Pirker
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
- Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria;
| | - Philipp Kroiss
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
- Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria;
| | - Dominik Kirchhofer
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
- Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria;
| | - Lisa Gabler
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
- Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria;
| | - Johannes Gojo
- Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria;
- Department of Pediatrics and Adolescent Medicine and Comprehensive Center for Pediatrics, Medical University of Vienna, 1090 Vienna, Austria
| | - Daniela Lötsch-Gojo
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
- Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria;
- Department of Neurosurgery, Medical University of Vienna, 1090 Vienna, Austria
| | - Mirjana Stojanovic
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
- Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria;
| | - Gerald Timelthaler
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
| | - Franziska Ferk
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
| | - Siegfried Knasmüller
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
| | - Johannes Reisecker
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
| | - Sabine Spiegl-Kreinecker
- Department of Neurosurgery, Neuromed Campus, Kepler University Hospital GmbH, Johannes Kepler University, 4040 Linz, Austria;
| | - Peter Birner
- Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, Austria;
| | - Matthias Preusser
- Division of Oncology, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria;
| | - Walter Berger
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; (C.D.); (C.P.); (P.K.); (D.K.); (L.G.); (D.L.-G.); (M.S.); (G.T.); (F.F.); (S.K.); (J.R.)
- Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria;
- Correspondence: ; Tel.: +43-(0)1-40160-57555
| |
Collapse
|
5
|
van der Westhuyzen AE, Ingels A, Rosière R, Amighi K, Oberer L, Gustafson KR, Wang D, Evidente A, Maddau L, Masi M, de Villiers A, Green IR, Berger W, Kornienko A, Mathieu V, van Otterlo WAL. Deciphering the chemical instability of sphaeropsidin A under physiological conditions - degradation studies and structural elucidation of the major metabolite. Org Biomol Chem 2020; 18:8147-8160. [PMID: 33016969 PMCID: PMC7881364 DOI: 10.1039/d0ob01586e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The fungal metabolite sphaeropsidin A (SphA) has been recognised for its promising cytotoxicity, particularly towards apoptosis- and multidrug-resistant cancers. Owing to its intriguing activity, the development of SphA as a potential anticancer agent has been pursued. However, this endeavour is compromised since SphA exhibits poor physicochemical stability under physiological conditions. Herein, SphA's instability in biological media was explored utilizing LC-MS. Notably, the degradation tendency was found to be markedly enhanced in the presence of amino acids in the cell medium utilized. Furthermore, the study investigated the presence of degradation adducts, including the identification, isolation and structural elucidation of a major degradation metabolite, (4R)-4,4',4'-trimethyl-3'-oxo-4-vinyl-4',5',6',7'-tetrahydro-3'H-spiro[cyclohexane-1,1'-isobenzofuran]-2-ene-2-carboxylic acid. Considering the reduced cytotoxic potency of aged SphA solutions, as well as that of the isolated degradation metabolite, the reported antiproliferative activity has been attributed primarily to the parent compound (SphA) and not its degradation species. The fact that SphA continues to exhibit remarkable bioactivity, despite being susceptible to degradation, motivates future research efforts to address the challenges associated with this instability impediment.
Collapse
Affiliation(s)
- Alet E van der Westhuyzen
- Department of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa.
| | - Aude Ingels
- Department of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium. and ULB Cancer Research Center, Université libre de Bruxelles (ULB), 1050 Bruxelles, Belgium
| | - Rémi Rosière
- Department of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium.
| | - Karim Amighi
- Department of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium.
| | - Lukas Oberer
- Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Basel, Switzerland
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, USA
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, USA
| | - Antonio Evidente
- Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126 Naples, Italy
| | - Lucia Maddau
- Department of Agriculture, Section of Plant Pathology and Entomology, University of Sassari, Viale Italia 39, 07100, Sassari, Italy
| | - Marco Masi
- Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126 Naples, Italy
| | - André de Villiers
- Department of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa.
| | - Ivan R Green
- Department of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa.
| | - Walter Berger
- Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Alexander Kornienko
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, Texas 78666, USA
| | - Veronique Mathieu
- Department of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium. and ULB Cancer Research Center, Université libre de Bruxelles (ULB), 1050 Bruxelles, Belgium
| | - Willem A L van Otterlo
- Department of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa.
| |
Collapse
|
6
|
Rittler D, Baranyi M, Molnár E, Garay T, Jalsovszky I, Varga IK, Hegedűs L, Aigner C, Tóvári J, Tímár J, Hegedűs B. The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb. Int J Mol Sci 2019; 20:ijms20194917. [PMID: 31623406 PMCID: PMC6801414 DOI: 10.3390/ijms20194917] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Revised: 09/24/2019] [Accepted: 09/27/2019] [Indexed: 12/22/2022] Open
Abstract
Malignant melanoma is one of the most metastatic cancer types, and despite recent success with novel treatment strategies, there is still a group of patients who do not respond to any therapies. Earlier, the prenylation inhibitor hydrophilic bisphosphonate zoledronic acid (ZA) was found to inhibit melanoma growth in vitro, but only a weaker effect was observed in vivo due to its hydrophilic properties. Recently, lipophilic bisphosphonates (such as BPH1222) were developed. Accordingly, for the first time, we compared the effect of BPH1222 to ZA in eight melanoma lines using viability, cell-cycle, clonogenic and spheroid assays, videomicroscopy, immunoblot, and xenograft experiments. Based on 2D and spheroid assays, the majority of cell lines were more sensitive to BPH. The activation of Akt and S6 proteins, but not Erk, was inhibited by BPH. Additionally, BPH had a stronger apoptotic effect than ZA, and the changes of Rheb showed a correlation with apoptosis. In vitro, only M24met cells were more sensitive to ZA than to BPH; however, in vivo growth of M24met was inhibited more strongly by BPH. Here, we present that lipophilic BPH is more effective on melanoma cells than ZA and identify the PI3K pathway, particularly Rheb as an important mediator of growth inhibition.
Collapse
Affiliation(s)
- Dominika Rittler
- Department of Pathology, Semmelweis University, H-1091 Budapest, Hungary.
| | - Marcell Baranyi
- Department of Pathology, Semmelweis University, H-1091 Budapest, Hungary.
| | - Eszter Molnár
- Department of Pathology, Semmelweis University, H-1091 Budapest, Hungary.
| | - Tamás Garay
- Department of Pathology, Semmelweis University, H-1091 Budapest, Hungary.
- Pázmány Péter Catholic University, Faculty of Information Technology and Bionics, H-1083 Budapest, Hungary.
- Oncology Center, Semmelweis University, H-1091 Budapest, Hungary.
| | - István Jalsovszky
- Eötvös Loránd University, Faculty of Science, Institute of Chemistry, Department of Organic Chemistry; H-1117 Budapest, Hungary.
| | - Imre Károly Varga
- Eötvös Loránd University, Faculty of Science, Institute of Chemistry, Department of Organic Chemistry; H-1117 Budapest, Hungary.
| | - Luca Hegedűs
- Department of Thoracic Surgery, Ruhrlandklinik, University Duisburg-Essen, D-45239 Essen, Germany.
| | - Clemens Aigner
- Department of Thoracic Surgery, Ruhrlandklinik, University Duisburg-Essen, D-45239 Essen, Germany.
| | - József Tóvári
- Department of Experimental Pharmacology, National Institute of Oncology, H-1122 Budapest, Hungary.
| | - József Tímár
- Department of Pathology, Semmelweis University, H-1091 Budapest, Hungary.
| | - Balázs Hegedűs
- Department of Pathology, Semmelweis University, H-1091 Budapest, Hungary.
- Department of Thoracic Surgery, Ruhrlandklinik, University Duisburg-Essen, D-45239 Essen, Germany.
| |
Collapse
|
7
|
Jomrich G, Maroske F, Stieger J, Preusser M, Ilhan-Mutlu A, Winkler D, Kristo I, Paireder M, Schoppmann SF. MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas. J Cancer 2018; 9:460-468. [PMID: 29483950 PMCID: PMC5820912 DOI: 10.7150/jca.22310] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Accepted: 11/26/2017] [Indexed: 12/19/2022] Open
Abstract
Background. Esophageal cancer is ranked in the top ten of diagnosed tumors worldwide. Even though improvements in survival could be noticed over the last years, prognosis remains poor. ETS translocation variant 1 (ETV1) is a member of a family of transcription factors and is phosphorylated by mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2). Aim of this study was to evaluate the prognostic role of MK2 and ETV1 in esophageal cancer. Methods. Consecutive patients that underwent surgical resection at the department of surgery at the Medical University of Vienna between 1991 and 2012 were included into this study. After microscopic analysis, tissue micro arrays (TMAs) were created and immunohistochemistry was performed with antibodies against MK2 and ETV1. Results. 323 patients were included in this study. Clinical data was achieved from a prospective patient data base. Nuclear overexpression of MK2 was observed in 143 (44.3%) cases for nuclear staining and in 142 (44.0%) cases a cytoplasmic overexpression of MK2 was observed. Nuclear and cytoplasmic ETV1 overexpression was detected in 20 cases (6.2%) and 30 cases (9.3%), respectively. In univariate survival analysis, cMK2 and nETV1 were found to be significantly associated with patients' overall survival. Whereas overexpression of cMK2 was associated with shorter, nETV1 was associated with longer overall survival. In multivariate survival analysis, both cMK2 and nETV1 were found to be independent prognostic factors for the subgroup of EAC as well. Discussion. Expression of MK2 and ETV1 are prognostic factors in patients, with esophageal adenocarcinoma.
Collapse
Affiliation(s)
- Gerd Jomrich
- Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC), Spitalgasse 23, 1090 Vienna, Austria
| | - Florian Maroske
- Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC), Spitalgasse 23, 1090 Vienna, Austria
| | - Jasmin Stieger
- Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC), Spitalgasse 23, 1090 Vienna, Austria
| | - Matthias Preusser
- Department of Medicine 1, Medical University of Vienna, Vienna, Austria. Comprehensive Cancer Center (CCC), Spitalgasse 23, 1090 Vienna, Austria
| | - Aysegül Ilhan-Mutlu
- Department of Medicine 1, Medical University of Vienna, Vienna, Austria. Comprehensive Cancer Center (CCC), Spitalgasse 23, 1090 Vienna, Austria
| | - Daniel Winkler
- Vienna University of Economics and Business, Welthandelsplatz 1, AD, 1020 Vienna, Austria
| | - Ivan Kristo
- Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC), Spitalgasse 23, 1090 Vienna, Austria
| | - Matthias Paireder
- Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC), Spitalgasse 23, 1090 Vienna, Austria
| | - Sebastian Friedrich Schoppmann
- Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC), Spitalgasse 23, 1090 Vienna, Austria
| |
Collapse
|
8
|
Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas. Cancer Chemother Pharmacol 2017; 79:971-983. [DOI: 10.1007/s00280-017-3293-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Accepted: 03/24/2017] [Indexed: 12/19/2022]
|
9
|
Dumitru C, Constantin C, Popp C, Cioplea M, Zurac S, Vassu T, Neagu M. Innovative array-based assay for omics pattern in melanoma. J Immunoassay Immunochem 2017; 38:343-354. [PMID: 28613106 DOI: 10.1080/15321819.2017.1340898] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Cutaneous melanoma remains a major health issue and still an important challenge for research. Thus, omics complex evaluation can provide a more specific molecular classification for this heterogeneous disease. Complex omics analysis based on genomic and proteomic microarrays can identify disease markers that prognosticate disease evolution or can monitor therapies efficacy. Among the technologies that gained momentum in the last years, array-based comparative genomic hybridization offered the possibility to analyze chromosomal numerical aberrations within cutaneous melanomas providing important support for molecular classification of melanoma tumors. This technology can identify new chromosomal alterations and discover new deregulated melanoma genes that can be further used as therapy targets. Integrating genetic profiling with clinical and pathological parameters would lead to seminal improvements in diagnosis, prognosis, and therapy.
Collapse
Affiliation(s)
- Carmen Dumitru
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
| | - Carolina Constantin
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
- b Department of Immunology , "Victor Babes" National Institute of Pathology , Bucharest , Romania
| | - Cristiana Popp
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
- c Department of Physiology "Carol Davila" University of Medicine and Pharmacy , Bucharest , Romania
| | - Mirela Cioplea
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
- c Department of Physiology "Carol Davila" University of Medicine and Pharmacy , Bucharest , Romania
| | - Sabina Zurac
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
- c Department of Physiology "Carol Davila" University of Medicine and Pharmacy , Bucharest , Romania
| | - Tatiana Vassu
- d Faculty of Biology , University of Bucharest , Bucharest , Romania
| | - Monica Neagu
- a Department of Pathology , "Colentina" Clinical Hospital , Bucharest , Romania
- b Department of Immunology , "Victor Babes" National Institute of Pathology , Bucharest , Romania
- d Faculty of Biology , University of Bucharest , Bucharest , Romania
| |
Collapse
|